|Application ||WB, IHC-P, IF, E|
|Calculated MW||55931 Da|
|Antigen Region||82-108 aa|
|Other Names||Cytochrome P450 2C19, 11413-, (R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, CYPIIC17, CYPIIC19, Cytochrome P450-11A, Cytochrome P450-254C, Mephenytoin 4-hydroxylase, CYP2C19|
|Target/Specificity||This CYP2C19 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 82-108 amino acids from the N-terminal region of human CYP2C19.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CYP2C19 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.|
|Cellular Location||Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CYP2C19 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within its gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes.
Shuldiner,A.R., JAMA 302 (8), 849-857 (2009) Nelson,D.R., Pharmacogenetics 14 (1), 1-18 (2004)
If you have any additional inquiries please email technical services at email@example.com.